| 301 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Switzerland
|
66 |
| 302 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
63 |
| 303 |
Apheresis |
Allogeneic
|
T -Cell Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
45 |
| 304 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Croatia
|
57 |
| 305 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
40 |
| 306 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Kazachstan
|
8 |
| 307 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
65 |
| 308 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
66 |
| 309 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
68 |
| 310 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
65 |
| 311 |
Apheresis |
Allogeneic
|
Diffuse Large B-Cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
63 |
| 312 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
66 |
| 313 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
44 |
| 314 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
57 |
| 315 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2026
|
Standard Therapy
|
UK
|
62 |
| 316 |
Apheresis |
Allogeneic
|
Aplastic Anemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
22 |
| 317 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
72 |
| 318 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
68 |
| 319 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Belgium
|
63 |
| 320 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
47 |
| 321 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
51 |
| 322 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
70 |
| 323 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Bulgaria
|
28 |
| 324 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
68 |
| 325 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
73 |
| 326 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
69 |
| 327 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
10 |
| 328 |
Apheresis |
Allogeneic
|
T-cell non-Hodgkin lymphoma / NK
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
19 |
| 329 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2026
|
Standard Therapy
|
Belgium
|
48 |
| 330 |
Apheresis |
Allogeneic
|
Essential Thrombocythemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
59 |
| 331 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Ukraine
|
58 |
| 332 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
72 |
| 333 |
Apheresis |
Allogeneic
|
B-ALL B-cell Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Netherlands
|
71 |
| 334 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
59 |
| 335 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
67 |
| 336 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
67 |
| 337 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
37 |
| 338 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
France
|
66 |
| 339 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
48 |
| 340 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
15 |
| 341 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
45 |
| 342 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
61 |
| 343 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
43 |
| 344 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
64 |
| 345 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
29 |
| 346 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Switzerland
|
69 |
| 347 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
61 |
| 348 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
67 |
| 349 |
Apheresis |
Allogeneic
|
Orofacial Myofunctional Disorders (OMDS); Primary Myelofibrosis (PMF) to secondary Acute Myeloid Leukemia (AML)
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
36 |
| 350 |
Apheresis |
Allogeneic
|
Chronic Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
66 |
| 351 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
66 |
| 352 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
57 |
| 353 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
India
|
51 |
| 354 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
25 |
| 355 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
35 |
| 356 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Finland
|
40 |
| 357 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
49 |
| 358 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
66 |
| 359 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
67 |
| 360 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
50 |
| 361 |
Apheresis |
Allogeneic
|
T Lymphblastic Leukemia/Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Canada
|
43 |
| 362 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
France
|
74 |
| 363 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Australia
|
67 |
| 364 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
59 |
| 365 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Czechia
|
44 |
| 366 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
56 |
| 367 |
Apheresis |
Autologous
|
Anaplastic T Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Portugal
|
23 |
| 368 |
Apheresis |
Autologous
|
Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
66 |
| 369 |
Apheresis |
Allogeneic
|
T-Cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
55 |
| 370 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
61 |
| 371 |
Apheresis |
Autologous
|
Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
53 |
| 372 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
56 |
| 373 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
69 |
| 374 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Lithuania
|
60 |
| 375 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
75 |
| 376 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
58 |
| 377 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
74 |
| 378 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
69 |
| 379 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
70 |
| 380 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Canada
|
25 |
| 381 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Sweden
|
65 |
| 382 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
72 |
| 383 |
Apheresis |
Allogeneic
|
Lymphoma Burkitt Histiocytic Sarcoma
|
Hematology
|
2026
|
Standard Therapy
|
Greece
|
12 |
| 384 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukaemia
|
Hematology
|
2026
|
Standard Therapy
|
France
|
69 |
| 385 |
Apheresis |
Allogeneic
|
Other Myelofibrosis/Myelosclerosis
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
69 |
| 386 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia FLT3-ITD positive
|
Hematology
|
2026
|
Standard Therapy
|
Romania
|
11 |
| 387 |
Apheresis |
Allogeneic
|
Myelofibrosis (MF)
|
Hematology
|
2026
|
Standard Therapy
|
Lithuania
|
67 |
| 388 |
Apheresis |
Allogeneic
|
X-ALD (E 71.3)
|
Hematology
|
2026
|
Standard Therapy
|
Czechia
|
5 |
| 389 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
73 |
| 390 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
36 |
| 391 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Netherlands
|
56 |
| 392 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
53 |
| 393 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Ukraine
|
39 |
| 394 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
24 |
| 395 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
62 |
| 396 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
70 |
| 397 |
Apheresis |
Allogeneic
|
Other Malignancy
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
71 |
| 398 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
62 |
| 399 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
59 |
| 400 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
70 |